According to the World Health Organization Chief Scientist Soumya Swaminathan, the emergency use listing (EUL) status of Covaxin will be decided in the next four to six weeks, as per a report released by Moneycontrol.
The coronavirus vaccine is indigenously developed by Bharat Biotech, with almost complete papers have been submitted by the company to the World Health Organisation for emergency use listing.
Many Indians who have taken the dose of the vaccine developed by Bharat Biotech but are currently excluded from the list of globally accepted vaccines, more International acceptance of the vaccine and its approval is significant, which will also boost the prospects of international travel.
While from the apex global health body, only six vaccines have EUL including Oxford, Moderna, AstraZeneca, Johnson and Johnson, Pfizer-BioNTech, Sinopharm, and Sinovac, ensuring supply for other nations, Covaxin shall also be allowed to join the World Health Organization’s COVAX vaccine alliance with this stamp.
The indigenous vaccine for coronavirus developed by Bharat Biotech was found to be 93% effective against severe COVID-19 along with 78% effective against mild, moderate, and severe COVID-19, reducing hospitalizations and 63% effective against asymptomatic COVID-19 transmission in the phase III data.
Against the Delta variant of the coronavirus disease, the indigenous vaccine was found to be 65% effective, while the company has said that the vaccine has been well-tolerated among participants showing minimal adverse effects post-immunization.